Enanta Pharmaceuticals Major Shareholder Saints Capital Granite, L.P. Sells 36,207 Shares (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) major shareholder Saints Capital Granite, L.P. sold 36,207 shares of Enanta Pharmaceuticals stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $21.71, for a total value of $786,053.97. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 1.43% during mid-day trading on Friday, hitting $20.62. The stock had a trading volume of 51,548 shares. Enanta Pharmaceuticals has a one year low of $14.31 and a one year high of $26.39. The stock has a 50-day moving average of $20.82 and a 200-day moving average of $19.39. The company’s market cap is $369.3 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.34) by $0.11. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.73 million. Analysts expect that Enanta Pharmaceuticals will post $-1.26 EPS for the current fiscal year.
Separately, analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 2nd. They now have a $25.40 price target on the stock. Five research analysts have rated the stock with a buy rating, Enanta Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $27.20.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.